ClinicalTrials.gov Protocol and Results Registration System (PRS) Receipt
Release Date: 05/23/2013

ClinicalTrials.gov ID: NCT00558272

Study Identification

Unique Protocol ID:	D8180C00034
Brief Title:	Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease
Official Title:	A Phase II, Randomised, Open-Label, Pilot Study to Evaluate the Safety and Effects on Bone Resorption of AZD0530 in Patients With Prostate Cancer or Breast Cancer With Metastatic Bone Disease.
Secondary IDs:	

Study Status

Record Verification:	May 2013
Overall Status:	Completed
Study Start:	February 2008
Primary Completion:	January 2010 [Actual]
Study Completion:	August 2012 [Actual]

Sponsor/Collaborators

Sponsor:	AstraZeneca
Responsible Party:	Sponsor
Collaborators:	

Oversight

FDA Regulated?:	Yes
Applicable Trial?:	Section 801 Clinical Trial? Yes

	Delayed Posting? No
IND/IDE Protocol?:	Yes
IND/IDE Information:	Grantor: CDER IND/IDE Number: 69,055 Serial Number: 007 Has Expanded Access? No
Review Board:	Approval Status: Approved Approval Number: 8/13/2007WIRB PR NO: 20070976 Board Name: WIRB Board Affiliation: Western Institutional Review Board Phone: 360.252.2500 Email: clientservices@wirb.com
Data Monitoring?:	Yes
Plan to Share Data?:	
Oversight Authorities:	United States: Food and Drug Administration Canada: Health Canada Denmark: Danish Medicines Agency Spain: Spanish Agency of Medicines Sweden: Medical Products Agency Norway: Norwegian Medicines Agency Portugal: National Pharmacy and Medicines Institute United Kingdom: Medicines and Healthcare Products Regulatory Agency

Study Description

Brief Summary:	The purpose of this study is to determine the effect of AZD0530 on subjects with breast cancer or prostate cancer with metastatic bone disease in comparison to zoledronic acid.
Detailed Description:	

Conditions

Conditions:	Breast Cancer Prostate Cancer Bone Neoplasms
Keywords:	breast cancer prostate cancer metastatic bone disease Subjects with breast cancer or prostate cancer with metastatic bone disease

Study Design

Study Type:	Interventional
Primary Purpose:	Treatment
Study Phase:	Phase 2
Intervention Model:	Parallel Assignment
Number of Arms:	2
Masking:	Open Label
Allocation:	Randomized
Endpoint Classification:	Safety/Efficacy Study
Enrollment:	139 [Actual]

Arms and Interventions

Arms	Assigned Interventions
Experimental: AZD0530 175 mg AZD0530 (saracatinib) 175 mg once daily	Drug: AZD0530 Daily oral dose Other Names: • Saracatinib
Experimental: Zoledronic Acid 4 mg Zoledronic Acid 4 mg on Day 1 of the 4-week treatment period	Drug: Zoledronic Acid Other Names: • Zometa

Outcome Measures

[See Results Section.]

Eligibility

Minimum Age:	18 Years
Maximum Age:	
Gender:	Both
Accepts Healthy Volunteers?:	No
Criteria:	Inclusion Criteria:

- Subjects 18 years or older with Prostate Cancer or Breast Cancer with Metastatic Bone Disease Have evidence of recurrence or disease progression
- At least one radiographically confirmed metastatic bone lesion
- No change of cancer therapy for at least 8 weeks before randomization

Exclusion Criteria:

- Have had any prior exposure to bisphosphonate
- Have had hip fractures or bilateral hip prothesis fracture of any kind or surgery to bone within the past 12 months
- Inadequate renal function or low haemoglobin
- Inadequate liver function as demonstrated by serum bilirubin ≥2 times the upper limits of reference range (ULRR) or by alanine aminotransferase (ALT), aspartate aminotransferase(AST) or ALP ≥2.5 times the ULRR (≥5 times the ULRR in the presence of liver metastases). If bone metastases are present and liver function is otherwise considered adequate by the investigator then elevated ALP will not exclude the patient.

Contacts/Locations

Study Officials: Richard Finkelman, DDS, PhD
Study Director
AstraZeneca

Meabe Aklilu, MD
Study Principal Investigator
Wake Forest University Health Sciences

Locations: Canada, Alberta
Research Site
Edmonton, Alberta, Canada

Canada, British Columbia
Research Site
Vancouver, British Columbia, Canada

Canada, Ontario
Research Site
Toronto, Ontario, Canada

Canada, Quebec
Research Site
Montreal, Quebec, Canada

Research Site
Quebec, Quebec, Canada

Denmark

Research Site
Arhus N, Denmark

Research Site
Frederica, Denmark

Research Site
Herlev, Denmark

Research Site
Holstebro, Denmark

United Kingdom
Research Site
Cardiff, United Kingdom

Research Site
Glasgow, United Kingdom

Research Site
Manchester, United Kingdom

Norway
Research Site
Kristiansand, Norway

Research Site
Oslo, Norway

Portugal
Research Site
Lisboa, Portugal

Spain
Research Site
Barcelona, Cataluna, Spain

Research Site
Lerida, Cataluna, Spain

Research Site
Valencia, Comunidad Valenciana, Spain

Sweden
Research Site
Uppsala, Sweden

United States, California
Research Site
Pleasant Hill, California, United States

Research Site
Sacramento, California, United States

United States, Connecticut
Research Site
Middlebury, Connecticut, United States

United States, Florida
Research Site
Aventura, Florida, United States

United States, Maryland
Research Site
Baltimore, Maryland, United States

United States, Michigan
Research Site
Ann Arbor, Michigan, United States

United States, North Carolina
Research Site
Winston-salem, North Carolina, United States

United States, New York
Research Site
Poughkeepsie, New York, United States

United States, Pennsylvania
Research Site
Hershey, Pennsylvania, United States

References

Citations:

Links: URL: http://www.astrazeneca-us.com/cancerstudylocator
Description Cancer Study Locator (US and Canada only)

Study Data/Documents:

Participant Flow

Recruitment Details	Randomised=full analysis set: AZD0530 175mg=69, Zoledronic acid 4mg=70; safety set: AZD0530 175mg=68, Zoledronic acid 4mg=69

Reporting Groups

	Description
AZD0530 175 mg	AZD0530 (saracatinib) 175 mg once daily
Zoledronic Acid 4 mg	Zoledronic Acid 4 mg on Day 1 of the 4-week treatment period

Overall Study

	AZD0530 175 mg	Zoledronic Acid 4 mg
Started	69 [1]	70 [1]
30 Days Follow-up	41 [2]	67 [2]
Completed	56 [3]	68 [3]
Not Completed	13	2
Adverse Event	10	0
Death	1	0
Dev. of study specific discon. criteria	1	0
AZ study team decision	0	1
Incorrectly enrolled	1	0
Withdrawal by Subject	0	1

[1] Randomised
[2] 30 days after last dose
[3] 4-week treatment period

Baseline Characteristics

Reporting Groups

	Description
AZD0530 175 mg	AZD0530 (saracatinib) 175 mg once daily
Zoledronic Acid 4 mg	Zoledronic Acid 4 mg on Day 1 of the 4-week treatment period

Baseline Measures

	AZD0530 175 mg	Zoledronic Acid 4 mg	Total
Number of Participants	69	70	139
Age, Continuous [units: Years] Mean (Standard Deviation)	67.6 (8.35)	67.3 (11.58)	67.4 (10.07)
Gender, Male/Female [units: Participants]			
Female	11	12	23
Male	58	58	116

Outcome Measures

1. Primary Outcome Measure:

Measure Title	Percentage Change From Baseline in Serum Beta C-terminal Cross-linking Telopeptide of Type I Collagen (betaCTX) at Week 4
Measure Description	Result at Week 4 minus result at baseline as a percentage of the result at baseline, based on log transformed data. Back transformation of the least squares (LS) mean.
Time Frame	Baseline to Week 4
Safety Issue?	No

Analysis Population Description

The number of participants analyzed reflected the number of paired serum samples per participant that yielded valid assay results, not the total number of participants or completers. The number of evaluable paired serum samples will therefore be a subset of the total number of participants.

Reporting Groups

	Description
AZD0530 175 mg	AZD0530 (saracatinib) 175 mg once daily

	Description
Zoledronic Acid 4 mg	Zoledronic Acid 4 mg on Day 1 of the 4-week treatment period

Measured Values

	AZD0530 175 mg	Zoledronic Acid 4 mg
Number of Participants Analyzed	46	65
Percentage Change From Baseline in Serum Beta C-terminal Cross-linking Telopeptide of Type I Collagen (betaCTX) at Week 4 [units: Percentage change in betaCTX] Geometric Mean (95% Confidence Interval)	-71.1 (-75.9 to -65.4)	-68.4 (-73.0 to -63.2)

2. Secondary Outcome Measure:

Measure Title	Percentage Change From Baseline in Serum Bone-specific Alkaline Phosphatase (bALP) at Week 4
Measure Description	Result at Week 4 minus result at baseline as a percentage of the result at baseline, based on log transformed data. Back transformation of the least squares (LS) mean.
Time Frame	Baseline to Week 4
Safety Issue?	No

Analysis Population Description

The number of participants analyzed reflected the number of paired serum samples per participant that yielded valid assay results, not the total number of participants or completers. The number of evaluable paired serum samples will therefore be a subset of the total number of participants.

Reporting Groups

	Description
AZD0530 175 mg	AZD0530 (saracatinib) 175 mg once daily
Zoledronic Acid 4 mg	Zoledronic Acid 4 mg on Day 1 of the 4-week treatment period

Measured Values

	AZD0530 175 mg	Zoledronic Acid 4 mg
Number of Participants Analyzed	48	66
Percentage Change From Baseline in Serum Bone-specific Alkaline Phosphatase (bALP) at Week 4 [units: Percentage change in bALP] Geometric Mean (95% Confidence Interval)	-13.2 (-24.4 to -0.3)	-3.1 (-13.9 to 9.1)

3. Secondary Outcome Measure:

Measure Title	Percentage Change From Baseline in Serum Cross-linked C-terminal Telopeptide of Type I Collagen (ICTP) at Week 4
Measure Description	Result at Week 4 minus result at baseline as a percentage of the result at baseline, based on log transformed data. Back transformation of the least squares (LS) mean.
Time Frame	Baseline to Week 4
Safety Issue?	No

Analysis Population Description

The number of participants analyzed reflected the number of paired serum samples per participant that yielded valid assay results, not the total number of participants or completers. The number of evaluable paired serum samples will therefore be a subset of the total number of participants.

Reporting Groups

	Description
AZD0530 175 mg	AZD0530 (saracatinib) 175 mg once daily
Zoledronic Acid 4 mg	Zoledronic Acid 4 mg on Day 1 of the 4-week treatment period

Measured Values

	AZD0530 175 mg	Zoledronic Acid 4 mg
Number of Participants Analyzed	47	66
Percentage Change From Baseline in Serum Cross-linked C-terminal Telopeptide of Type I Collagen (ICTP) at Week 4 [units: Percentage change in ICTP] Geometric Mean (95% Confidence Interval)	-40.2 (-46.3 to -33.4)	7.4 (-2.0 to 17.7)

4. Secondary Outcome Measure:

Measure Title	Percentage Change From Baseline in Serum N-terminal Propeptide of Type I Procollagen (PINP) at Week 4
Measure Description	Result at Week 4 minus result at baseline as a percentage of the result at baseline, based on log transformed data. Back transformation of the least squares (LS) mean.
Time Frame	Baseline to Week 4
Safety Issue?	No

Analysis Population Description

The number of participants analyzed reflected the number of paired serum samples per participant that yielded valid assay results, not the total number of participants or completers. The number of evaluable paired serum samples will therefore be a subset of the total number of participants.

Reporting Groups

	Description
AZD0530 175 mg	AZD0530 (saracatinib) 175 mg once daily
Zoledronic Acid 4 mg	Zoledronic Acid 4 mg on Day 1 of the 4-week treatment period

Measured Values

	AZD0530 175 mg	Zoledronic Acid 4 mg
Number of Participants Analyzed	48	66
Percentage Change From Baseline in Serum N-terminal Propeptide of Type I Procollagen (PINP) at Week 4 [units: Percentage change in PINP] Geometric Mean (95% Confidence Interval)	-26.1 (-36.0 to -14.7)	-29.5 (-37.7 to -20.3)

5. Secondary Outcome Measure:

Measure Title	Percentage Change From Baseline in Serum Tartrate-resistant Acid Phosphatase 5b (TRAP5b) at Week 4
Measure Description	Result at Week 4 minus result at baseline as a percentage of the result at baseline, based on log transformed data. Back transformation of the least squares (LS) mean.
Time Frame	Baseline to Week 4
Safety Issue?	No

Analysis Population Description

The number of participants analyzed reflected the number of paired serum samples per participant that yielded valid assay results, not the total number of participants or completers. The number of evaluable paired serum samples will therefore be a subset of the total number of participants.

Reporting Groups

	Description
AZD0530 175 mg	AZD0530 (saracatinib) 175 mg once daily
Zoledronic Acid 4 mg	Zoledronic Acid 4 mg on Day 1 of the 4-week treatment period

Measured Values

	AZD0530 175 mg	Zoledronic Acid 4 mg
Number of Participants Analyzed	48	65
Percentage Change From Baseline in Serum Tartrate-resistant Acid Phosphatase 5b (TRAP5b) at Week 4 [units: Percentage change in TRAP5b] Geometric Mean (95% Confidence Interval)	-36.9 (-42.7 to -30.4)	-43.4 (-48.0 to -38.4)

6. Secondary Outcome Measure:

Measure Title	Percentage Change From Baseline in Urine N-terminal Cross-linking Telopeptide of Type I Collagen Normalised to Creatinine (NTx/Cr) at Week 4
Measure Description	Result at Week 4 minus result at baseline as a percentage of the result at baseline, based on log transformed data. Back transformation of the least squares (LS) mean.
Time Frame	Baseline to Week 4
Safety Issue?	No

Analysis Population Description

The number of participants analyzed reflected the number of paired serum samples per participant that yielded valid assay results, not the total number of participants or completers. The number of evaluable paired serum samples will therefore be a subset of the total number of participants.

Reporting Groups

	Description
AZD0530 175 mg	AZD0530 (saracatinib) 175 mg once daily
Zoledronic Acid 4 mg	Zoledronic Acid 4 mg on Day 1 of the 4-week treatment period

Measured Values

	AZD0530 175 mg	Zoledronic Acid 4 mg
Number of Participants Analyzed	46	62
Percentage Change From Baseline in Urine N-terminal Cross-linking Telopeptide of Type I Collagen Normalised to Creatinine (NTx/Cr) at Week 4 [units: Percentage change in NTx/Cr] Geometric Mean (95% Confidence Interval)	-57.2 (-65.7 to -46.6)	-70.1 (-75.4 to -63.8)

7. Secondary Outcome Measure:

Measure Title	Percentage Change From Baseline in Urine Alpha-alpha C-terminal Cross-linking Telopeptide of Type I Collagen Normalised to Creatinine (aaCTx/Cr) at Week 4
Measure Description	Result at Week 4 minus result at baseline as a percentage of the result at baseline, based on log transformed data. Back transformation of the least squares (LS) mean.
Time Frame	Baseline to Week 4
Safety Issue?	No

Analysis Population Description

The number of participants analyzed reflected the number of paired serum samples per participant that yielded valid assay results, not the total number of participants or completers. The number of evaluable paired serum samples will therefore be a subset of the total number of participants.

Reporting Groups

	Description
AZD0530 175 mg	AZD0530 (saracatinib) 175 mg once daily
Zoledronic Acid 4 mg	Zoledronic Acid 4 mg on Day 1 of the 4-week treatment period

Measured Values

	AZD0530 175 mg	Zoledronic Acid 4 mg
Number of Participants Analyzed	41	49
Percentage Change From Baseline in Urine Alpha-alpha C-terminal Cross-linking Telopeptide of Type I Collagen Normalised to Creatinine (aaCTx/Cr) at Week 4 [units: Percentage change in aaCTx/Cr] Geometric Mean (95% Confidence Interval)	-68.2 (-76.7 to -56.5)	-82.8 (-87.1 to -77.0)

8. Secondary Outcome Measure:

Measure Title	Saracatinib: Area Under the Curve at Steady State (AUCss)
Measure Description	Previous studies have shown that saracatinib reduces osteoclast function and bone resorption. Bone turnover, the combined result of bone formation and bone resorption, can be assessed in real time by measuring specific markers of bone turnover in serum and in urine. These markers were assessed in a study of patients with metastatic bone disease treated with saracatinib. Specific assays are available to quantitate these markers in serum and urine. In this study the effects of saracatinib on bone turnover were compared with the effects of zoledronic acid, a marketed drug known to inhibit bone resorption in cancer patients with bone metastatses.

Time Frame	Pre-dose on days 8, 15, 29; 2 hours, 4 hours, 6 hours, 9 hours post dose on day 29
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
AZD0530 175 mg	AZD0530 (saracatinib) 175 mg once daily
Zoledronic Acid 4 mg	Zoledronic Acid 4 mg on Day 1 of the 4-week treatment period

Measured Values

	AZD0530 175 mg	Zoledronic Acid 4 mg
Number of Participants Analyzed	51	0
Saracatinib: Area Under the Curve at Steady State (AUCss) [units: ng•hr/ml] Median (Full Range)	7261 (3960 to 21500)	

9. Secondary Outcome Measure:

Measure Title	Saracatinib: Plasma Clearance at Steady State (CLss/F)
Measure Description	
Time Frame	Pre-dose on days 8, 15, 29; 2 hours, 4 hours, 6 hours, 9 hours post dose on day 29
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
AZD0530 175 mg	AZD0530 (saracatinib) 175 mg once daily
Zoledronic Acid 4 mg	Zoledronic Acid 4 mg on Day 1 of the 4-week treatment period

Measured Values

	AZD0530 175 mg	Zoledronic Acid 4 mg
Number of Participants Analyzed	51	0
Saracatinib: Plasma Clearance at Steady State (CLss/F) [units: L/h] Median (Full Range)	24.10 (8.15 to 44.2)	

10. Secondary Outcome Measure:

Measure Title	Saracatinib: Maximum Plasma Concentration at Steady State (Css,Max)
Measure Description	
Time Frame	Pre-dose on days 8, 15, 29; 2 hours, 4 hours, 6 hours, 9 hours post dose on day 29
Safety Issue?	No

Analysis Population Description

[Not Specified]

Reporting Groups

	Description
AZD0530 175 mg	AZD0530 (saracatinib) 175 mg once daily
Zoledronic Acid 4 mg	Zoledronic Acid 4 mg on Day 1 of the 4-week treatment period

Measured Values

	AZD0530 175 mg	Zoledronic Acid 4 mg
Number of Participants Analyzed	51	0
Saracatinib: Maximum Plasma Concentration at Steady State (Css,Max) [units: ng/ml] Median (Full Range)	396.0 (190 to 1170)	

11. Secondary Outcome Measure:

Measure Title	Saracatinib: Minimum Plasma Concentration at Steady State (Css,Min)

Measure Description	
Time Frame	Pre-dose on days 8, 15, 29; 2 hours, 4 hours, 6 hours, 9 hours post dose on day 29
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
AZD0530 175 mg	AZD0530 (saracatinib) 175 mg once daily
Zoledronic Acid 4 mg	Zoledronic Acid 4 mg on Day 1 of the 4-week treatment period

Measured Values

	AZD0530 175 mg	Zoledronic Acid 4 mg
Number of Participants Analyzed	51	0
Saracatinib: Minimum Plasma Concentration at Steady State (Css,Min) [units: ng/ml] Median (Full Range)	229.0 (99.1 to 770)	

12. Secondary Outcome Measure:

Measure Title	Saracatinib: Time to Cssmax (Tmax)
Measure Description	
Time Frame	Pre-dose on days 8, 15, 29; 2 hours, 4 hours, 6 hours, 9 hours post dose on day 29
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
AZD0530 175 mg	AZD0530 (saracatinib) 175 mg once daily
Zoledronic Acid 4 mg	Zoledronic Acid 4 mg on Day 1 of the 4-week treatment period

Measured Values

	AZD0530 175 mg	Zoledronic Acid 4 mg
Number of Participants Analyzed	51	0
Saracatinib: Time to Cssmax (Tmax) [units: h] Median (Full Range)	4.0 (2 to 9)	

13. Secondary Outcome Measure:

Measure Title	N-desmethyl Metabolite of Saracatinib: Area Under the Curve at Steady State (AUCss)
Measure Description	
Time Frame	Pre-dose on days 8, 15, 29; 2 hours, 4 hours, 6 hours, 9 hours post dose on day 29
Safety Issue?	No

Analysis Population Description

[Not Specified]

Reporting Groups

	Description
AZD0530 175 mg	AZD0530 (saracatinib) 175 mg once daily
Zoledronic Acid 4 mg	Zoledronic Acid 4 mg on Day 1 of the 4-week treatment period

Measured Values

	AZD0530 175 mg	Zoledronic Acid 4 mg
Number of Participants Analyzed	51	0
N-desmethyl Metabolite of Saracatinib: Area Under the Curve at Steady State (AUCss) [units: ng.h/ml] Median (Full Range)	1069 (529 to 5100)	

14. Secondary Outcome Measure:

Measure Title	N-desmethyl Metabolite of Saracatinib: Maximum Plasma Concentration at Steady State (Css,Max)
Measure Description	

Time Frame	Pre-dose on days 8, 15, 29; 2 hours, 4 hours, 6 hours, 9 hours post dose on day 29
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
AZD0530 175 mg	AZD0530 (saracatinib) 175 mg once daily
Zoledronic Acid 4 mg	Zoledronic Acid 4 mg on Day 1 of the 4-week treatment period

Measured Values

	AZD0530 175 mg	Zoledronic Acid 4 mg
Number of Participants Analyzed	51	0
N-desmethyl Metabolite of Saracatinib: Maximum Plasma Concentration at Steady State (Css,Max) [units: ng/ml] Median (Full Range)	62.80 (25.3 to 253)	

15. Secondary Outcome Measure:

Measure Title	N-desmethyl Metabolite of Saracatinib: Minimum Plasma Concentration at Steady State (Css,Min)
Measure Description	
Time Frame	Pre-dose on days 8, 15, 29; 2 hours, 4 hours, 6 hours, 9 hours post dose on day 29
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
AZD0530 175 mg	AZD0530 (saracatinib) 175 mg once daily
Zoledronic Acid 4 mg	Zoledronic Acid 4 mg on Day 1 of the 4-week treatment period

Measured Values

	AZD0530 175 mg	Zoledronic Acid 4 mg
Number of Participants Analyzed	51	0
N-desmethyl Metabolite of Saracatinib: Minimum Plasma Concentration at Steady State (Css,Min) [units: ng/ml] Median (Full Range)	34.30 (16.6 to 230)	

16. Secondary Outcome Measure:

Measure Title	N-desmethyl Metabolite of Saracatinib: AUCss Metabolite to Parent Ratio
Measure Description	
Time Frame	Pre-dose on days 8, 15, 29; 2 hours, 4 hours, 6 hours, 9 hours post dose on day 29
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
AZD0530 175 mg	AZD0530 (saracatinib) 175 mg once daily
Zoledronic Acid 4 mg	Zoledronic Acid 4 mg on Day 1 of the 4-week treatment period

Measured Values

	AZD0530 175 mg	Zoledronic Acid 4 mg
Number of Participants Analyzed	51	0
N-desmethyl Metabolite of Saracatinib: AUCss Metabolite to Parent Ratio [units: Ratio] Median (Full Range)	0.1420 (0.081 to 0.354)	

17. Secondary Outcome Measure:

Measure Title	N-desmethyl Metabolite of Saracatinib: Time to Cssmax (Tmax)

Measure Description	
Time Frame	Pre-dose on days 8, 15, 29; 2 hours, 4 hours, 6 hours, 9 hours post dose on day 29
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
AZD0530 175 mg	AZD0530 (saracatinib) 175 mg once daily
Zoledronic Acid 4 mg	Zoledronic Acid 4 mg on Day 1 of the 4-week treatment period

Measured Values

	AZD0530 175 mg	Zoledronic Acid 4 mg
Number of Participants Analyzed	51	0
N-desmethyl Metabolite of Saracatinib: Time to Cssmax (Tmax) [units: h] Median (Full Range)	2.0 (2 to 9)	

Reported Adverse Events

Time Frame	[Not specified]
Additional Description	safety set: AZD0530 175mg=68, Zoledronic acid 4mg=69

Reporting Groups

	Description
AZD0530 175 mg	AZD0530 (saracatinib) 175 mg once daily
Zoledronic Acid 4 mg	Zoledronic Acid 4 mg on Day 1 of the 4-week treatment period

Serious Adverse Events

	AZD0530 175 mg	Zoledronic Acid 4 mg
	Affected/At Risk (%)	Affected/At Risk (%)
Total	11/68 (16.18%)	4/69 (5.8%)
Blood and lymphatic system disorders		
Anaemia [A] †	1/68 (1.47%)	0/69 (0%)
Cardiac disorders		
Cardiac Arrest [A] †	1/68 (1.47%)	0/69 (0%)
Myocardial Infarction [A] †	1/68 (1.47%)	0/69 (0%)
Gastrointestinal disorders		
Vomiting [A] †	1/68 (1.47%)	0/69 (0%)
General disorders		
General Physical Health Deterioration [A] †	0/68 (0%)	1/69 (1.45%)
Pyrexia [A] †	1/68 (1.47%)	0/69 (0%)
Infections and infestations		
Pneumonia [A] †	2/68 (2.94%)	0/69 (0%)
Viral Infection [A] †	1/68 (1.47%)	0/69 (0%)
Injury, poisoning and procedural complications		
Blood Creatinine Increased [A] †	0/68 (0%)	1/69 (1.45%)
Metabolism and nutrition disorders		
Dehydration [A] †	0/68 (0%)	1/69 (1.45%)
Musculoskeletal and connective tissue disorders		
Bone Pain [A] †	0/68 (0%)	1/69 (1.45%)
Muscle Spasms [A] †	0/68 (0%)	1/69 (1.45%)
Musculoskeletal Pain [A] †	0/68 (0%)	1/69 (1.45%)
Nervous system disorders		

	AZD0530 175 mg	Zoledronic Acid 4 mg
	Affected/At Risk (%)	Affected/At Risk (%)
Cerebral Haemorrhage [A] †	1/68 (1.47%)	0/69 (0%)
Renal and urinary disorders		
Renal Failure [A] †	1/68 (1.47%)	0/69 (0%)
Renal Failure Acute [A] †	1/68 (1.47%)	0/69 (0%)
Respiratory, thoracic and mediastinal disorders		
Pulmonary Oedema [A] †	1/68 (1.47%)	0/69 (0%)
Vascular disorders		
Deep Vein Thrombosis [A] †	1/68 (1.47%)	0/69 (0%)

† Indicates events were collected by systematic assessment.
A Term from vocabulary, MedDRA 13.0

Other Adverse Events

Frequency Threshold Above Which Other Adverse Events are Reported: 5%

	AZD0530 175 mg	Zoledronic Acid 4 mg
	Affected/At Risk (%)	Affected/At Risk (%)
Total	51/68 (75%)	46/69 (66.67%)
Gastrointestinal disorders		
Constipation [A] †	10/68 (14.71%)	5/69 (7.25%)
Diarrhoea [A] †	13/68 (19.12%)	4/69 (5.8%)
Nausea [A] †	16/68 (23.53%)	3/69 (4.35%)
Vomiting [A] †	7/68 (10.29%)	5/69 (7.25%)
General disorders		
Asthenia [A] †	4/68 (5.88%)	1/69 (1.45%)
Fatigue [A] †	5/68 (7.35%)	4/69 (5.8%)
Influenza Like Illness [A] †	3/68 (4.41%)	8/69 (11.59%)

	AZD0530 175 mg	Zoledronic Acid 4 mg
	Affected/At Risk (%)	Affected/At Risk (%)
Oedema Peripheral [A] †	4/68 (5.88%)	2/69 (2.9%)
Pyrexia [A] †	4/68 (5.88%)	6/69 (8.7%)
Infections and infestations		
Influenza [A] †	0/68 (0%)	11/69 (15.94%)
Urinary Tract Infection [A] †	6/68 (8.82%)	2/69 (2.9%)
Metabolism and nutrition disorders		
Decreased Appetite [A] †	8/68 (11.76%)	1/69 (1.45%)
Musculoskeletal and connective tissue disorders		
Arthralgia [A] †	4/68 (5.88%)	7/69 (10.14%)
Back Pain [A] †	8/68 (11.76%)	4/69 (5.8%)
Bone Pain [A] †	3/68 (4.41%)	5/69 (7.25%)
Musculoskeletal Pain [A] †	5/68 (7.35%)	8/69 (11.59%)
Neck Pain [A] †	1/68 (1.47%)	4/69 (5.8%)
Pain In Extremity [A] †	1/68 (1.47%)	7/69 (10.14%)
Nervous system disorders		
Headache [A] †	5/68 (7.35%)	5/69 (7.25%)
Respiratory, thoracic and mediastinal disorders		
Dyspnoea [A] †	5/68 (7.35%)	2/69 (2.9%)

† Indicates events were collected by systematic assessment.
A Term from vocabulary, MedDRA 13.0

Limitations and Caveats

Non-compliant patients were excluded from the biomarker analysis, in order to accurately assess effects due to treatment. The compliance criteria did not apply to the zoledronic acid arm, which led to an imbalance in the number of subjects analysed.

More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

If a Study Site, or an investigator, requests permission to publish data from this study, any such publication (including oral presentations) is to be agreed with AstraZeneca prior to publication.

Results Point of Contact:

Name/Official Title: Gerard Lynch
Organization: AstraZeneca
Phone:
Email: aztrial_results_posting@astrazeneca.com